CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
CytoMed Therapeutics (NASDAQ: GDTC) announced on October 22, 2025 that Executive Chairman Peter Choo purchased an additional 105,824 shares in open-market trades, raising his personal holding to 187,500 shares (2.50%).
He also holds shares through related entities — Glorious Finance Limited (55% owner) and sole ownership of EP Capital Inc — which together represent 2,282,422 shares (19.45%). In aggregate he controls 2,388,246 shares, or 21.95% of outstanding shares. The company said it will update on any further purchases and advised investors to exercise caution when trading until further announcements.
CytoMed Therapeutics (NASDAQ: GDTC) ha annunciato il 22 ottobre 2025 che l'amministratore delegato esecutivo Peter Choo ha acquistato ulteriori 105.824 azioni nelle negoziazioni di mercato aperto, portando la sua quota personale a 187.500 azioni (2,50%).
Possiede anche azioni tramite entità correlate — Glorious Finance Limited (55% proprietario) e la piena proprietà di EP Capital Inc — che insieme rappresentano 2.282.422 azioni (19,45%). In totale controlla 2.388.246 azioni, ovvero il 21,95% delle azioni ordinarie. L'azienda ha dichiarato che fornirà aggiornamenti su eventuali ulteriori acquisti e ha consigliato agli investitori di essere prudenti nelle negoziazioni fino a ulteriori comunicazioni.
CytoMed Therapeutics (NASDAQ: GDTC) anunció el 22 de octubre de 2025 que el presidente ejecutivo Peter Choo compró unas 105,824 acciones adicionales en operaciones de mercado abierto, elevando su participación personal a 187,500 acciones (2.50%).
También posee acciones a través de entidades relacionadas — Glorious Finance Limited (55% dueño) y la propiedad exclusiva de EP Capital Inc — que en conjunto representan 2,282,422 acciones (19.45%). En total controla 2,388,246 acciones, o el 21.95% de las acciones en circulación. La empresa dijo que actualizará sobre cualquier compra adicional y aconsejó a los inversores que sean cautelosos al comerciar hasta nuevos anuncios.
CytoMed Therapeutics (NASDAQ: GDTC)는 2025년 10월 22일에, 이사회 의장 Peter Choo가 추가로 105,824주를 공개시장 거래에서 매수하여 개인 보유 수를 187,500주(2.50%)로 확대했다고 발표했다.
또한 관련 기관을 통해 주식을 보유하고 있는데 — Glorious Finance Limited(지분 55%)와 단독 소유의 EP Capital Inc — 이들 합산은 2,282,422주(19.45%)를 나타낸다. 총합으로 그는 2,388,246주, 발행 주식의 21.95%를 지배한다. 회사는 추가 매수에 대해서도 업데이트할 것이며, 추가 공지가 있을 때까지 거래 시 주의할 것을 투자자들에게 권고했다고 밝혔다.
CytoMed Therapeutics (NASDAQ: GDTC) a annoncé le 22 octobre 2025 que le président exécutif Peter Choo a acheté 105 824 actions supplémentaires lors d'opérations sur le marché libre, portant sa participation personnelle à 187 500 actions (2,50%).
Il détient également des actions par le biais d'entités associées — Glorious Finance Limited (55 % propriétaire) et la propriété exclusive de EP Capital Inc — qui représentent ensemble 2 282 422 actions (19,45%). Au total, il contrôle 2 388 246 actions, soit 21,95% des actions en circulation. La société a déclaré qu'elle mettrait à jour tout achat ultérieur et a conseillé aux investisseurs d'être prudents lors des transactions jusqu'à de nouvelles annonces.
CytoMed Therapeutics (NASDAQ: GDTC) kündigte am 22. Oktober 2025 an, dass der Executive Chairman Peter Choo in offenen Märkten weitere 105.824 Aktien gekauft hat und seine persönliche Beteiligung auf 187.500 Aktien (2,50%) erhöht hat.
Er hält auch Anteile über verbundene Einheiten — Glorious Finance Limited (55% Eigentümer) und alleiniger Eigentümer von EP Capital Inc — die zusammen 2.282.422 Aktien (19,45%) repräsentieren. Insgesamt kontrolliert er 2.388.246 Aktien, bzw. 21,95% der ausstehenden Aktien. Das Unternehmen sagte, es werde über weitere Käufe berichten und riet Investoren, beim Handel bis zu weiteren Ankündigungen Vorsicht walten zu lassen.
CytoMed Therapeutics (NASDAQ: GDTC) أعلنت في 22 أكتوبر 2025 أن رئيس مجلس الإدارة التنفيذي Peter Choo اشترى 105,824 سهماً إضافياً في صفقات السوق المفتوحة، مرتفعاً بمجموع حصته الشخصية إلى 187,500 سهماً (2.50%).
كما يملك أسهماً من خلال كيانات مرتبطة — Glorious Finance Limited (55% مالك) وملكية EP Capital Inc الكاملة — والتي تمثل معاً 2,282,422 سهماً (19.45%). بإجمالها يسيطر على 2,388,246 سهماً، أي 21.95% من إجمالي الأسهم القائمة. قالت الشركة إنها ستقوم بتحديث المستثمرين عن أي شراء إضافي ونصحتهم بالحذر في التداول حتى صدور إعلان آخر.
CytoMed Therapeutics (NASDAQ: GDTC) 于 2025年10月22日宣布，执行主席 Peter Choo 在公开市场交易中再度购买了105,824股，个人持股达到187,500股（2.50%）。
他还通过相关实体持有股份——Glorious Finance Limited（55%股权）和< b>EP Capital Inc的全资所有权——共同合计代表2,282,422股（19.45%）。合计他控制2,388,246股，约占流通股本的21.95%。公司表示将就任何进一步购买进行更新，并建议投资者在直到进一步公告前谨慎交易。
- Open-market purchase of 105,824 shares on Oct 22, 2025
- Aggregate ownership increased to 2,388,246 shares (21.95%)
- High ownership concentration: Chairman holds 21.95% of shares
- Company advisory instructs investors to exercise caution until updates
Insights
Chairman increased personal stake to
His purchases add 105,824 shares to existing holdings, taking total ownership to
Key dependencies include the size and timing of any future purchases and whether these holdings change board dynamics or control thresholds. The statement contains forward-looking rationale from the chairman but offers no new operational or clinical milestones to validate value creation.
Watch for further filings and disclosures of subsequent purchases, any Schedule 13D/13G amendments, and material corporate actions over the next 30–90 days. Those items determine whether this ownership change alters governance, voting control, or strategic options.
SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding in the Company through recent open-market purchases of 105,824 shares. This is on top of 187,500 shares which he holds personally, bringing his personal stake in CytoMed to
On his purchases, Chairman Peter remarked "I see value and potential in our novel proprietary technologies to treat cancers in an affordable and “off-the-shelf” manner amidst rising investors’ interest in biotherapeutics in Asia, especially China. In addition, Southeast Asia’s expanding healthcare and medical travel ecosystem, coupled with the rising cost of healthcare in the West, present unique opportunities to those who can innovate and provide cost-competitive patient access. The region’s accelerating biotech momentum, M&A opportunities and supportive regulatory environment further reinforces my purchase decision.”
The Company will provide updates on further purchases by our Chairman and will announce when available. Shareholders and investors are advised to exercise caution when dealing in the Company’s securities until further announcements are made.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.
Forward Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
FAQ
What stake does CytoMed Chairman Peter Choo own after the Oct 22, 2025 purchases (GDTC)?
How many additional shares did the CytoMed Chairman buy on Oct 22, 2025 (GDTC)?
How much of CytoMed does Peter Choo hold personally versus via entities (GDTC)?
Does CytoMed plan to disclose further purchases by its Chairman (GDTC)?
What warning did CytoMed give investors after the Chairman's purchases (GDTC)?
